SGLT2 inhibitors × blood pressure

TrialDiabetes, obesity & metabolism2014

Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.

M A Nauck et al.PubMed ↗Publisher ↗

What the trial testedas reported · 814 people · 2014

Not counted

Probably lowered blood pressure

−5.10kg−5.70 to −4.40

As reported

difference −5.1 kg, 95% CI −5.70 to −4.40

One number in the abstract

the abstract, start to end

versus glipizide differences of -5.1 kg (95% CI: -5.7,-4.4) and -3.9

← favours treatmentfavours comparator →
could be chance
Blood pressure
−5.1−5.70 to −4.40
SGLT2 inhibitorsSulfonylureas & glinidesBlood pressure
1 / 3

44 papers cite it

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
this paperpooled ittrialcites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 24919526